0.670
-0.03 (-3.97%)
| Penutupan Terdahulu | 0.698 |
| Buka | 0.723 |
| Jumlah Dagangan | 30,140 |
| Purata Dagangan (3B) | 105,590 |
| Modal Pasaran | 7,370,000 |
| Harga / Jualan (P/S) | 0.340 |
| Harga / Buku (P/B) | 1.47 |
| Julat 52 Minggu |
| Margin Keuntungan | 9.19% |
| Margin Operasi (TTM) | 9.24% |
| EPS Cair (TTM) | 0.170 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 58.20% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 232.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 43.88% |
| Nisbah Semasa (MRQ) | 2.46 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Pharmaceutical Retailers (US) | Bercampur | Bercampur |
| Pharmaceutical Retailers (Global) | Bercampur | Menaik | |
| Stok | Cellyan Biotechnology Co., Ltd | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | -2.5 |
| Purata | -0.75 |
|
Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and (ii) OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China’s OTC pharmaceutical cross-border e-commerce market. |
|
| Sektor | Healthcare |
| Industri | Pharmaceutical Retailers |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 68.01% |
| % Dimiliki oleh Institusi | 0.47% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 16 Jan 2026 | Pengumuman | Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |